

Oncologic Drugs Advisory Committee

September 1, 2009

Hilton Washington DC/Silver Spring, Silver Spring, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

S. Gail Eckhardt, M.D. (Chair)

Professor and Division Head, Medical Oncology
University of Colorado at Denver
12801 E. 17th Avenue
L18-8124
Campus Box 8117
Aurora, CO 80045

Ralph Freedman, M.D., Ph.D. (P.M. Session Only)

Clinical Professor
Department of Gynecologic Oncology
The University of Texas
M.D. Anderson Cancer Center
Unit 1362
Houston, TX 77230

Michael Link, M.D.

The Lydia J. Lee Professor of Pediatrics
Chief, Division of Hematology/Oncology
Stanford University School of Medicine
1000 Welch Road, Suite 300
Palo Alto, CA 94304

Gary Lyman, M.D., M.P.H.

Director, Health Services and Outcomes
Research Program- Oncology
Duke University Medical Center
Box 3645
Durham, NC 27710

Virginia Mason, R.N. (Consumer Representative)

Executive Director
Inflammatory Breast Cancer Research Foundation
P.O. Box 786
Citronelle, AL 36522

Ronald Richardson, M.D.

Consultant, Department of Medical Oncology
Mayo Clinic
200 First Street, SW, Gonda 10
Rochester, MN 55905

Mikael Sekeres, M.D., M.S. (P.M. Session Only)

Associate Professor of Medicine
Staff
Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
9500 Euclid Avenue, Desk R35
Cleveland, OH 44195

Margaret Tempero, M.D.

Deputy Director, UCSF Helen Diller Family
Comprehensive Cancer Center
University of California, San Francisco
UCSF Cancer Center
1600 Divisadero Street, Room B726
Box 1770
San Francisco, CA 94115

Wyndham Wilson, M.D.

Chief, Lymphoma Therapeutics Section
Metabolism Branch
Center for Cancer Research
National Cancer Institute
9000 Rockville Pike, Bldg. 10, Room 4N-115
Rockville, MD 20892

Oncologic Drugs Advisory Committee

September 1, 2009

Hilton Washington DC/Silver Spring, Silver Spring, Maryland

INDUSTRY REPRESENTATIVE (Non-Voting)

Gregory Curt, M.D.

U.S. Medical Science Lead, Emerging Products

AstraZeneca Oncology

P.O. Box 223

Garrett Park, MD 20896

TEMPORARY VOTING MEMBERS (Morning Session)

Lodovico Balducci, M.D.

Program Leader

Senior Adult Oncology Program

Moffitt Cancer Center

12902 Magnolia Drive, MCC SA Prog

Tampa, FL 33612

John Barrett, M.D.

Section Chief: Stem Cell Allotransplantation,
Hematology Branch,

National Heart Lung and Blood Institute,

National Institutes of Health

10 Center Drive

10-CRC-Hatfield Clinical Research Center, 3-
5330

Bethesda, MD 20892

Arthur Flatau, Ph.D. (Patient Representative)

Austin, TX 78704

Thomas Fleming, Ph.D.

Professor

Department of Biostatistics

University of Washington, Seattle

Box 357232

Seattle, WA 98195

Gail Roboz, M.D.

Associate Professor of Medicine

Director, Leukemia Program and Department of
Medicine

Weill Medical College of Cornell University

Division of Hematology and Oncology

520 East 70th Street

Starr 340A

New York, NY 10021

GUEST SPEAKER (Non-Voting)

Elihu Estey, M.D. (Guest Speaker)

Member Fred Hutchinson Cancer Research
Center, Seattle

Professor of Medicine, Division of Hematology

University of Washington School of Medicine

825 Eastlake Ave East

Seattle, WA 98109

Oncologic Drugs Advisory Committee

September 1, 2009

Hilton Washington DC/Silver Spring, Silver Spring, Maryland

TEMPORARY VOTING MEMBERS (Afternoon Session)

Lodovico Balducci, M.D.

Program Leader
Senior Adult Oncology Program
Moffitt Cancer Center
12902 Magnolia Drive, MCC SA Prog
Tampa, FL 33612

John Barrett, M.D.

Section Chief: Stem Cell Allotransplantation,
Hematology Branch,
National Heart Lung and Blood Institute,
National Institutes of Health
10 Center Drive
10-CRC-Hatfield Clinical Research Center, 3-
5330
Bethesda, MD 2089

Arthur Flatau, Ph.D. (Patient Representative)

Austin, TX 78704

Thomas Fleming, Ph.D.

Professor
Department of Biostatistics
University of Washington, Seattle
Box 357232
Seattle, WA 98195

FDA Non-Voting

Morning Session

Richard Pazdur, M.D.

Director
Office of Oncology Drug Products (OODP),
OND, CDER, FDA

Robert Justice, M.D.

Director
Division of Drug Oncology Products (DDOP),
OODP, OND, CDER, FDA

John Johnson, M.D.

Medical Team Leader
DDOP, OODP, OND, CDER, FDA

Martin Cohen, M.D.

Medical Officer
DDOP, OODP, OND, CDER, FDA

Afternoon Session

Richard Pazdur, M.D.

Director
Office of Oncology Drug Products (OODP),
OND, CDER, FDA

Robert Justice, M.D.

Director
Division of Drug Oncology Products (DDOP),
OODP, OND, CDER, FDA

Albert Deisseroth, M.D.

Medical Officer
DDOP, OODP, OND, CDER, FDA

Robert Kane, M.D.

Medical Officer
DDOP, OODP, OND, CDER, FDA

Huanyu Chen, Ph.D.

Statistical Reviewer - Drug Oncology
Division of Biostatistics 5 (DB5),
Office of Biostatistics (OB),
Office of Translational Science (OTS),
CDER, FDA